Zhonghua bing li xue za zhi Chinese journal of pathology
-
Zhonghua Bing Li Xue Za Zhi · Sep 2015
[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
To study the prevalence of ALK, ROS1 and RET fusion genes in non-small cell lung cancer (NSCLC), and its correlation with clinicopathologic features. ⋯ The ALK, ROS1 and RET fusion gene mutation rates in NSCLC are low, they represent some specific molecular subtypes of NSCLC. Genetic testing has significant meaning to guide clinical targeted therapy.
-
Zhonghua Bing Li Xue Za Zhi · Aug 2015
[Expression of microRNA in ALK-negative anaplastic large cell lymphoma and CD30-positive peripheral T cell lymphoma, not otherwise specified].
To study the role of microRNAs (miRNAs) in ALK-negative anaplastic large cell lymphoma and CD30 positive peripheral T cell lymphoma (not otherwise specified), and discuss the pathogenesis of miRNAs in ALK-negative anaplastic large cell lymphoma. ⋯ MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified). MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
-
Zhonghua Bing Li Xue Za Zhi · Apr 2015
[Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma].
To investigate mutations frequencies of KRAS,NRAS and BRAF genes in colorectal carcinoma. ⋯ Mutations at exon 2 of KRAS gene have the highest frequency in colorectal carcinoma. Expanding the detection sites of KRAS gene combined with NRAS and BRAF genes may help to identify patients who will most likely benefit from targeted therapies.
-
Zhonghua Bing Li Xue Za Zhi · Mar 2015
[ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives].
To explore the automated immunostainer screening anaplastic lymphoma kinase (ALK) gene fusion non-small cell lung cancer (NSCLC) and clinicopathological characteristics of the molecular subtype lung cancers. Methods Five hundred and sixty-six cases of NSCLC were collected over a 16 month period. The test for ALK was performed by Ventana automated immunostainer with anti-ALK D5F3. ⋯ Twelve of fifteen patients received crizotinib therapy and remained stable. Conclusions NSCLC with ALK gene rearrangement shows distinctive clinical and histological features. Ventana-IHC may he a feasible and valid technique for detection of ALK rearrangement in NSCLC.